Exelixis Inc - ESG Rating & Company Profile powered by AI
This report of Exelixis Inc was prepared by All Street Sevva using advanced artificial intelligence. This SDG rating for Exelixis Inc indicates the company's transparency towards the United Nations SDGs. Other companies in the scoring peer group for Exelixis Inc are displayed.
Exelixis Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.2; made up of an environmental score of 5.7, social score of 6.0 and governance score of 6.0.
6.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 563 | ReproCell Inc | 6.3 | High |
| 563 | Venus Remedies Ltd | 6.3 | High |
| 586 | Exelixis Inc | 6.2 | High |
| 586 | Althea Group Holdings Ltd | 6.2 | High |
| 586 | AlzeCure Pharma AB | 6.2 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Exelixis Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Exelixis Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Exelixis Inc report the average age of the workforce?
Sign up for free to unlockDoes Exelixis Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Exelixis Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Exelixis Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Exelixis Inc offer flexible work?
Sign up for free to unlockDoes Exelixis Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Exelixis Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Exelixis Inc conduct supply chain audits?
Sign up for free to unlockDoes Exelixis Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Exelixis Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Exelixis Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Exelixis Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Exelixis Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Exelixis Inc disclose water use targets?
Sign up for free to unlockDoes Exelixis Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Exelixis Inc have a product recall in the last two years?
Sign up for free to unlockDoes Exelixis Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Exelixis Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Exelixis Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Exelixis Inc disclose parental leave metrics?
Sign up for free to unlockDoes Exelixis Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Exelixis Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Exelixis Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Exelixis Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Exelixis Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Exelixis Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Exelixis Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Exelixis Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Exelixis Inc disclose its waste policy?
Sign up for free to unlockDoes Exelixis Inc report according to TCFD requirements?
Sign up for free to unlockDoes Exelixis Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Exelixis Inc disclose energy use targets?
Sign up for free to unlockDoes Exelixis Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Exelixis Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Exelixis Inc
These potential risks are based on the size, segment and geographies of the company.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.